| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 29th June 2020 | Raymond Debbane | 740 | Grant/award etc. | $0.00 | |
| 29th June 2020 | Christopher J Sobecki | 740 | Grant/award etc. | $0.00 | |
| 24th June 2020 | Lonnel Coats | 2,250 | Grant/award etc. | $0.00 | |
| 19th June 2020 | Lonnel Coats | 1,312 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Judith L Swain | 3,466 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Frank Palantoni | 3,466 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Robert J Md Lefkowitz | 3,466 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Raymond Debbane | 3,466 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Philippe Amouyal | 3,466 | Exercise of derivative | $0.00 | |
| 26th April 2020 | Sam L Barker | 3,466 | Exercise of derivative | $0.00 |
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995.
Ticker: LXRX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1062822
Employees: 184
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $87 M (0%)
Inventory, Net: $4 M (-5%)
Other Assets, Current: $9 M (77%)
Assets, Current: $246 M (-27%)
Property, Plant and Equipment, Net: $12 M (-17%)
Other Assets, Noncurrent: $1 M (-12%)
Assets: $323 M (-22%)
Long-term Debt, Current Maturities: $10 M (-5%)
Accounts Payable, Current: $30 M (144%)
Accrued Liabilities, Current: $57 M (36%)
Liabilities, Current: $98 M (49%)
Long-term Debt, Excluding Current Maturities: $235 M (0%)
Other Liabilities, Noncurrent: $862 Th (-21%)
Liabilities: $333 M (10%)
Common Stock, Value, Issued: $108 Th (1%)
Common Stock, Shares, Issued: $108 Th (1%)
Retained Earnings (Accumulated Deficit): $1 B (10%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $312 Th (271%)
Treasury Stock, Value: $48 Th (26%)
Treasury Stock, Shares: $8 Th (94%)
Stockholders' Equity (Parent): $11 M (-90%)
Liabilities and Equity: $323 M (-22%)
Revenue: $25 Th (-24%)
Cost of Revenue: $728 Th (-43%)
Research and Development: $57 M (-49%)
Operating Income/Loss: $65 M (-49%)
EPS (basic): $0.65 (-48%)
